<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02911792</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20160262H</org_study_id>
    <nct_id>NCT02911792</nct_id>
  </id_info>
  <brief_title>Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration</brief_title>
  <acronym>Hyper</acronym>
  <official_title>Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or
      without microalbuminuria with dapagliflozin or metformin for 4 months. The metformin-treated
      group will serve as controls for improved glycemic control, since the investigators have
      shown that insulin therapy to normalize A1c reduces hyperfiltration and kidney size in T1DM
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hyperfiltration is a characteristic feature in experimental models of diabetes and is
      causally related to an increase in intraglomerular pressure. In newly diagnosed diabetic
      patients, both type 1 and type 2, hyperfiltration and enlarged kidney size commonly are
      observed, and these hemodynamic/anatomic abnormalities are associated with an increased risk
      for the development of diabetic nephropathy.

      In poorly controlled diabetic individuals, the filtered load of glucose is markedly increased
      and glucose - with sodium - reabsorption by the SGLT2 transporter in the proximal tubule is
      augmented. As a consequence sodium delivery to the macula densa is reduced, making the kidney
      think that it is under perfused and this results in afferent renal arteriolar vasodilation.
      The efferent arteriole of the hyperfiltrating diabetic kidney also is hypersensitive to
      angiotensin II despite the absence of systemic RAS activation. The net result of these
      hemodynamic changes is an increase in intraglomerular pressure and hyperfiltration. Further,
      angiotensin is a potent growth factor and contributes to the increase in size of individual
      glomeruli and total kidney size. Since the intraglomerular pressure is related to the radius
      (r3) by the Law of LaPlace, the increase in glomerular size also contributes to
      hyperfiltration.

      Based upon the preceding sequence, it follows that a drug that blocks glucose, along with
      sodium, reabsorption in the proximal tubule would enhance sodium delivery to the macula
      densa, cause afferent renal arteriolar constriction, reduce intraglomerular
      pressure/hyperfiltration, and decrease kidney size. In hyperfiltering diabetic patients with
      microalbuminuria, the investigators also would expect the microalbuminuria to decrease.
      Consistent with this scenario, animal studies have documented that both acute and chronic
      inhibition of SGLT2 decreases hyperfiltration and prevents diabetic nephropathy. A recent
      study in hyperfiltering type 1 diabetic patients treated with empagliflozin has provided
      additional support for the tubular glomerular feedback hypothesis.

      The investigators propose to treat newly diagnosed, hyperfiltering T2DM patients with or
      without microalbuminuria with dapagliflozin or metformin for 4 months. The metformin-treated
      group will serve as controls for improved glycemic control, since the investigators have
      shown that insulin therapy to normalize A1c reduces hyperfiltration and kidney size in T1DM
      patients
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2016</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>GFR (glomerular filtration rate) change after treatment with Dapagliflozin</measure>
    <time_frame>4 months</time_frame>
    <description>Change from baseline in GFR after treatment with dapagliflozin for 4 months in the hyperfiltering diabetic group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GFR (glomerular filtration rate) change after treatment with Metformin</measure>
    <time_frame>4 months</time_frame>
    <description>Change from baseline in GFR after treatment with metformin for 4 months in the hyperfiltering diabetic group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GFR (glomerular filtration rate) change after treatment with Dapagliflozin in normofiltering group</measure>
    <time_frame>4 months</time_frame>
    <description>Change from baseline in GFR in the normofiltering group following 4 months of treatment with dapagliflozin</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to dapagliflozin, 5 mg/day. After 2 weeks (Visit 5), dapagliflozin will be increased to 10 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be randomized to metformin-XR, 1000 mg/day. After 2 weeks (Visit 5), metformin will be increased to 1000 mg bid (twice a day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>SGLT2 inhibitor</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Farxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Oral diabetes medicine that helps control blood sugar levels.</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>Metformin-XR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed, drug naïve, hyperfiltering and normofiltration patients with type 2
             diabetes mellitus (T2DM)

          -  Hyperfiltration is defined by GFR &gt;135 ml/min•1.73m2

          -  Normofiltration by a GFR = 90-134 ml/min•1.73m2

          -  BMI = 20-45 kg/m2

          -  HbA1c = 7.5% to 12%

          -  Willingness to participate in the 16 week study protocol

          -  Hematocrit &gt;34%

          -  GAD antibody negative

          -  BP &lt; 145/90 mmHg

        Exclusion Criteria:

          -  &gt; 300 mg/day albumin excretion

          -  Ingestion of medications known to interfere with the renin-angiotensin system or renal
             function, including diuretic therapy

          -  Hospitalization for unstable angina, history of recent macrovascular
             (MI/stroke/TIA/ACS) disease, coronary artery revascularization (within 2 months prior
             to enrollment)

          -  Proliferative diabetic retinopathy

          -  History of cancer or major organ system disease

          -  New York Heart class II-IV heart failure Severe hepatic insufficiency and/or
             significant abnormal liver function defined as aspartate aminotransferase (AST) and/or
             alanine aminotransferase (ALT) &gt; 3x ULN or total bilirubin &gt; 2.0 mg/dL (34.2 µmo/L)

          -  Treatment with steroids, beta blockers, alpha blockers, antiobesity drugs

          -  Pregnant or nursing mothers

          -  Premenopausal females who are not practicing acceptable contraceptive methods
             Participation in another trial with an investigational drug within 30 days Alcohol or
             drug abuse within the preceding 6 months

          -  Any condition, psychiatric or medical, which in the opinion of the investigator would
             interfere with the successful completion of the study

          -  Orthostatic hypotension (&gt; 15/10 mmHg decrease upon standing for 3 minutes)

          -  Positive serologic evidence of current infectious liver disease including Hepatitis B
             viral antibody IGM, Hepatitis B surface antigen, Hepatitis C virus antibody and HIV

          -  Volume depleted patients

          -  Estimated glomerular filtration rate &lt;60 mL/min•1.73m2. Patients at risk for volume
             depletion due to co-existing conditions or concomitant medications, such as loop
             diuretics should have careful monitoring of their volume status
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sanford Burnham Prebys Medical Discovery Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32827</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Pratley, MD</last_name>
      <phone>407-745-2145</phone>
      <email>rpratley@SBPdiscovery.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern Medical School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Molitch, MD</last_name>
      <phone>312-503-4130</phone>
      <email>molitch@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>George Bakris, MD</last_name>
      <phone>773-702-7936</phone>
      <email>gbakris@medicine.bsd.uchicago.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ralph A DeFronzo, MD</last_name>
      <phone>210-567-6691</phone>
      <email>defronzo@uthscsa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Monica Palomo, BS</last_name>
      <phone>210-567-6710</phone>
      <email>palomom@uthscsa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ralph A DeFronzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eugenio Cersosimo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Health Systems Texas Diabetic Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugenio Cersosimo, MD</last_name>
      <phone>210-358-7200</phone>
      <email>cersosimo@uthscsa.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Tuttle, MD</last_name>
      <phone>509-340-0930</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baker Medical Research Institute and Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark Cooper, MD</last_name>
      <phone>61385321362</phone>
      <email>mark.cooper@bakeridi.edu.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jerums G, Premaratne E, Panagiotopoulos S, MacIsaac RJ. The clinical significance of hyperfiltration in diabetes. Diabetologia. 2010 Oct;53(10):2093-104. doi: 10.1007/s00125-010-1794-9. Epub 2010 May 23. Review.</citation>
    <PMID>20496053</PMID>
  </reference>
  <reference>
    <citation>Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia. 2009 Apr;52(4):691-7. doi: 10.1007/s00125-009-1268-0. Epub 2009 Feb 7.</citation>
    <PMID>19198800</PMID>
  </reference>
  <reference>
    <citation>Tuttle KR, Bruton JL, Perusek MC, Lancaster JL, Kopp DT, DeFronzo RA. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med. 1991 Jun 6;324(23):1626-32. Erratum in: N Engl J Med 1991 Dec 5;325(23):1666.</citation>
    <PMID>2030719</PMID>
  </reference>
  <reference>
    <citation>Stanton RC. Sodium glucose transport 2 (SGLT2) inhibition decreases glomerular hyperfiltration: is there a role for SGLT2 inhibitors in diabetic kidney disease? Circulation. 2014 Feb 4;129(5):542-4. doi: 10.1161/CIRCULATIONAHA.113.007071. Epub 2013 Dec 13.</citation>
    <PMID>24334174</PMID>
  </reference>
  <reference>
    <citation>Abdul-Ghani MA, Norton L, Defronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011 Aug;32(4):515-31. doi: 10.1210/er.2010-0029. Epub 2011 May 23. Review.</citation>
    <PMID>21606218</PMID>
  </reference>
  <reference>
    <citation>Vallon V, Richter K, Blantz RC, Thomson S, Osswald H. Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption. J Am Soc Nephrol. 1999 Dec;10(12):2569-76.</citation>
    <PMID>10589696</PMID>
  </reference>
  <reference>
    <citation>Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014 Feb 4;129(5):587-97. doi: 10.1161/CIRCULATIONAHA.113.005081. Epub 2013 Dec 13.</citation>
    <PMID>24334175</PMID>
  </reference>
  <reference>
    <citation>Zatz R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest. 1986 Jun;77(6):1925-30.</citation>
    <PMID>3011862</PMID>
  </reference>
  <reference>
    <citation>Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int. 2000 May;57(5):1803-17. Review.</citation>
    <PMID>10792600</PMID>
  </reference>
  <reference>
    <citation>Anderson S, Vora JP. Current concepts of renal hemodynamics in diabetes. J Diabetes Complications. 1995 Oct-Dec;9(4):304-7. Review.</citation>
    <PMID>8573753</PMID>
  </reference>
  <reference>
    <citation>Ellis EN, Steffes MW, Goetz FC, Sutherland DE, Mauer SM. Glomerular filtration surface in type I diabetes mellitus. Kidney Int. 1986 Apr;29(4):889-94.</citation>
    <PMID>3712971</PMID>
  </reference>
  <reference>
    <citation>Schwieger J, Fine LG. Renal hypertrophy, growth factors, and nephropathy in diabetes mellitus. N Engl J Med 312:617-21, 1985</citation>
  </reference>
  <reference>
    <citation>Malatiali S, Francis I, Barac-Nieto M. Phlorizin prevents glomerular hyperfiltration but not hypertrophy in diabetic rats. Exp Diabetes Res. 2008;2008:305403. doi: 10.1155/2008/305403.</citation>
    <PMID>18769499</PMID>
  </reference>
  <reference>
    <citation>Thomson SC, Rieg T, Miracle C, Mansoury H, Whaley J, Vallon V, Singh P. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol. 2012 Jan 1;302(1):R75-83. doi: 10.1152/ajpregu.00357.2011. Epub 2011 Sep 21.</citation>
    <PMID>21940401</PMID>
  </reference>
  <reference>
    <citation>Pei F, Li BY, Zhang Z, Yu F, Li XL, Lu WD, Cai Q, Gao HQ, Shen L. Beneficial effects of phlorizin on diabetic nephropathy in diabetic db/db mice. J Diabetes Complications. 2014 Sep-Oct;28(5):596-603. doi: 10.1016/j.jdiacomp.2014.04.010. Epub 2014 Apr 24.</citation>
    <PMID>24927646</PMID>
  </reference>
  <reference>
    <citation>Bakker J, Olree M, Kaatee R, de Lange EE, Moons KG, Beutler JJ, Beek FJ. Renal volume measurements: accuracy and repeatability of US compared with that of MR imaging. Radiology. 1999 Jun;211(3):623-8.</citation>
    <PMID>10352583</PMID>
  </reference>
  <results_reference>
    <citation>Hostetter TH, Troy JL, Brenner BM. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int. 1981 Mar;19(3):410-5.</citation>
    <PMID>7241881</PMID>
  </results_reference>
  <results_reference>
    <citation>Brenner BM, Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA. The role of glomerular hyperfiltration in the initiation and progression of diabetic nephropathy. Acta Endocrinol Suppl (Copenh). 1981;242:7-10.</citation>
    <PMID>6940408</PMID>
  </results_reference>
  <results_reference>
    <citation>Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med. 1982 Mar;72(3):375-80. Review.</citation>
    <PMID>7036732</PMID>
  </results_reference>
  <results_reference>
    <citation>Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, Carrara F, Cella C, Ferrari S, Stucchi N, Parvanova A, Iliev I, Dodesini AR, Trevisan R, Bossi A, Zaletel J, Remuzzi G; GFR Study Investigators. Glomerular hyperfiltration and renal disease progression in type 2 diabetes. Diabetes Care. 2012 Oct;35(10):2061-8. Epub 2012 Jul 6.</citation>
    <PMID>22773704</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2016</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Eugenio Cersosimo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>hyperfiltering</keyword>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan to make individual participant data available</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

